1042 related articles for article (PubMed ID: 34380327)
1. Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls.
Cohen Sedgh R; Moon J; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Aug; 14(8):e007476. PubMed ID: 34380327
[TBL] [Abstract][Full Text] [Related]
2. Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
Eworuke E; Shinde M; Hou L; Paterson MJ; Jensen PB; Maro JC; Rai A; Scarnecchia D; Pennap D; Woronow D; Ghosh RE; Welburn S; Pottegard A; Platt RW; Lee H; Bradley MC
BMJ Open; 2023 Apr; 13(4):e070985. PubMed ID: 37068898
[TBL] [Abstract][Full Text] [Related]
3. A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
Hedenmalm K; Quinten C; Kurz X; Bradley M; Lee H; Eworuke E
Eur J Clin Pharmacol; 2023 Jun; 79(6):849-858. PubMed ID: 37095262
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin Receptor Blocker-Related Sprue-like Enteropathy: Review of Food and Drug Administration Adverse Event Reporting System.
Meader R; Papasotiriou S; Ahdi H; Dang H; Ehrenpreis ED
Ann Pharmacother; 2024 May; 58(5):494-500. PubMed ID: 37559251
[TBL] [Abstract][Full Text] [Related]
7. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
ARB Trialists Collaboration
J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
[TBL] [Abstract][Full Text] [Related]
8. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
[TBL] [Abstract][Full Text] [Related]
9. A Retrospective Cohort Study of the 2018 Angiotensin Receptor Blocker Recalls and Subsequent Drug Shortages in Patients With Hypertension.
Devine JW; Tadrous M; Hernandez I; Callaway Kim K; Rothenberger SD; Mukhopadhyay N; Gellad WF; Suda KJ
J Am Heart Assoc; 2024 Jan; 13(1):e032266. PubMed ID: 38156554
[TBL] [Abstract][Full Text] [Related]
10. Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Yoo YG; Lim MJ; Kim JS; Jeong HE; Ko H; Shin JY
Medicine (Baltimore); 2023 Nov; 102(46):e36098. PubMed ID: 37986329
[TBL] [Abstract][Full Text] [Related]
11. Current Status of Angiotensin Receptor Blocker Recalls.
Gunasekaran PM; Chertow GM; Bhalla V; Byrd JB
Hypertension; 2019 Dec; 74(6):1275-1278. PubMed ID: 31630573
[TBL] [Abstract][Full Text] [Related]
12. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
[TBL] [Abstract][Full Text] [Related]
14. Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany.
Rudolph UM; Enners S; Kieble M; Mahfoud F; Böhm M; Laufs U; Schulz M
J Hum Hypertens; 2021 Oct; 35(10):903-911. PubMed ID: 33057175
[TBL] [Abstract][Full Text] [Related]
15. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
Charoo NA; Ali AA; Buha SK; Rahman Z
AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
Maniadakis N; Ekman M; Fragoulakis V; Papagiannopoulou V; Yfantopoulos J
Eur J Health Econ; 2011 Jun; 12(3):253-61. PubMed ID: 20411401
[TBL] [Abstract][Full Text] [Related]
17. Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
Byrd JB; Chertow GM; Bhalla V
N Engl J Med; 2019 Apr; 380(17):1589-1591. PubMed ID: 30865819
[No Abstract] [Full Text] [Related]
18. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
[TBL] [Abstract][Full Text] [Related]
19. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Belz GG; Butzer R; Kober S; Mang C; Mutschler E
Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
[TBL] [Abstract][Full Text] [Related]
20. Photosensitivity with Angiotensin II Receptor Blockers: A Retrospective Study Using Data from VigiBase(®).
Viola E; Coggiola Pittoni A; Drahos A; Moretti U; Conforti A
Drug Saf; 2015 Oct; 38(10):889-94. PubMed ID: 26187686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
